VIP impairs acquisition of the macrophage proinflammatory polarization profile
暂无分享,去创建一个
A. Puig-Kröger | C. Martínez | R. Gomariz | I. Gutiérrez-Cañas | M. Carrión | S. Pérez-García | Y. Juarranz | L. Estrada‐Capetillo | A. Puig‐Kröger
[1] R. Ramhorst,et al. Trophoblast cells primed with vasoactive intestinal peptide enhance monocyte migration and apoptotic cell clearance through αvβ3 integrin portal formation in a model of maternal-placental interaction. , 2015, Molecular human reproduction.
[2] J. Rodríguez-Frade,et al. Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect , 2015, Journal of leukocyte biology.
[3] Joel W. Graff,et al. A Systematic Approach to Identify Markers of Distinctly Activated Human Macrophages , 2015, Front. Immunol..
[4] I. McInnes,et al. Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases , 2015, Pharmacological Reviews.
[5] Cristina Municio,et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A‐dependent pro‐inflammatory profile , 2015, The Journal of pathology.
[6] D. Ganea,et al. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases , 2015, Acta physiologica.
[7] I. González-Álvaro,et al. The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP , 2014, Journal of Molecular Medicine.
[8] S. Goerdt,et al. Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.
[9] M. Mellado,et al. Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells , 2014, Journal of Molecular Neuroscience.
[10] Yong-ming Yao,et al. Macrophage Polarization in Inflammatory Diseases , 2014, International journal of biological sciences.
[11] I. González-Álvaro,et al. Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis , 2014, PloS one.
[12] I. González-Álvaro,et al. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. , 2013, Rheumatology.
[13] M. Sweet,et al. An mRNA atlas of G protein-coupled receptor expression during primary human monocyte/macrophage differentiation and lipopolysaccharide-mediated activation identifies targetable candidate regulators of inflammation. , 2013, Immunobiology.
[14] W. Savino,et al. Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP , 2013, PloS one.
[15] M. Wolzt,et al. VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model , 2013, Journal of Translational Medicine.
[16] O. Fardel,et al. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. , 2013, Cellular immunology.
[17] S. Biswas,et al. Macrophage polarization and plasticity in health and disease , 2012, Immunologic Research.
[18] Alberto Mantovani,et al. Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.
[19] C. Martínez,et al. Effect of VIP on the balance between cytokines and master regulators of activated helper T cells , 2012, Immunology and cell biology.
[20] R. Gomariz,et al. RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. , 2011, Arthritis and rheumatism.
[21] A. Puig-Kröger,et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. , 2011, Blood.
[22] W. Mosgoeller,et al. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients , 2010, Peptides.
[23] A. Puig-Kröger,et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. , 2009, Cancer research.
[24] J. Edwards,et al. Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.
[25] C. Martínez,et al. VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts. , 2008, Molecular immunology.
[26] C. Tsatsanis,et al. Vasoactive intestinal peptide suppresses toll-like receptor 4 expression in macrophages via Akt1 reducing their responsiveness to lipopolysaccharide. , 2008, Molecular immunology.
[27] R. Gomariz,et al. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. , 2008, Arthritis and rheumatism.
[28] Javier Martín,et al. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. , 2008, Arthritis and rheumatism.
[29] Mario Delgado,et al. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy , 2007, Annals of the rheumatic diseases.
[30] P. Preshaw,et al. Pivotal Advance: Vasoactive intestinal peptide inhibits up‐regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages , 2007, Journal of leukocyte biology.
[31] C. Martínez,et al. VIP–PACAP System in Immunity , 2006, Annals of the New York Academy of Sciences.
[32] C. Martínez,et al. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. , 2006, Rheumatology.
[33] T. Ottenhoff,et al. Phenotypic and functional profiling of human proinflammatory type‐1 and anti‐inflammatory type‐2 macrophages in response to microbial antigens and IFN‐γ‐ and CD40L‐mediated costimulation , 2006, Journal of leukocyte biology.
[34] A. Couvineau,et al. VPAC receptors for VIP and PACAP. , 2002, Receptors & channels.
[35] Mario Delgado,et al. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease , 2001, Nature Medicine.
[36] M. O'dorisio,et al. Selective Gene Expression and Activation-Dependent Regulation of Vasoactive Intestinal Peptide Receptor Type 1 and Type 2 in Human T Cells1 , 2001, The Journal of Immunology.
[37] M. Delgado,et al. Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Nuclear Factor-κB-dependent Gene Activation at Multiple Levels in the Human Monocytic Cell Line THP-1* , 2001, The Journal of Biological Chemistry.
[38] M. Delgado,et al. Immunology of VIP: a review and therapeutical perspectives. , 2000, Current pharmaceutical design.
[39] M. Delgado,et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. , 2001, The Journal of biological chemistry.
[40] E. Muñoz-Elías,et al. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells , 1999, Journal of Neuroimmunology.
[41] E. Muñoz-Elías,et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. , 1999, Journal of immunology.
[42] E. Muñoz-Elías,et al. Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun* , 1998, The Journal of Biological Chemistry.
[43] M. Goldman,et al. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. , 1998, Immunology letters.